News
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?
Axsome Therapeutics' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over
2 Unstoppable Growth Stocks to Buy While Share Prices Are Low
A look at the facts will often reveal businesses that are poised for future growth and/or show no signs of slowing down. The stocks for these types of businesses tend to be particularly valuable to
2 Unstoppable Growth Stocks to Buy While Share Prices Are Low
A look at the facts will often reveal businesses that are poised for future growth and/or show no signs of slowing down. The stocks for these types of businesses tend to be particularly valuable to
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Which Healthcare Company Will Be the First to Get to a $1 Trillion Market Cap?
There are several healthcare companies with market caps in the hundreds of billions. However, there isn't one among this group that is approaching the $1 trillion mark just yet. There are four
Which Healthcare Company Will Be the First to Get to a $1 Trillion Market Cap?
There are several healthcare companies with market caps in the hundreds of billions. However, there isn't one among this group that is approaching the $1 trillion mark just yet. There are four
Why 2023 Could Be a Tough Year for AbbVie Stock
At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. It even has the added bonus of an attractive dividend yield of 3.7%. But there are some
Why Shares of TG Therapeutics Soared on Tuesday
Shares of TG Therapeutics (NASDAQ: TGTX) were up by 18% as of mid-afternoon Tuesday after reports that the biotech's multiple sclerosis therapy Briumvi would have better-than-expected sales in its
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
Shares of Adaptimmune Therapeutics (NASDAQ: ADAP) were up as much as 9.7% early Tuesday after the clinical-stage biotech announced that it had reached an agreement with GSK (NYSE: GSK) to return the